Assessment of oncological safety and utility of hysteroscopy in high grade endometrial cancers: Results from an Israel gynecologic oncology group study.

Endometrial cancer High-grade Hysteroscopy Survival

Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
17 Dec 2023
Historique:
received: 25 09 2023
revised: 29 11 2023
accepted: 15 12 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 20 12 2023
Statut: aheadofprint

Résumé

To compare survival measures of women with Stage I high-grade endometrial cancer who underwent either hysteroscopy or a non-hysteroscopic procedure as a diagnostic procedure. 298 patients with stage I high grade endometrial cancer who underwent surgery between 2002 and 2014. Patients were divided into two groups: hysteroscopy and non-hysteroscopy (curettage or office endometrial biopsy). Clinical, pathological, and survival measures were compared between the groups. High grade histology included endometroid grade -3, uterine serous papillary carcinoma, clear cell carcinoma, and carcinosarcoma. There were 71 patients in the hysteroscopy group and 227 patients in the non-hysteroscopy group. The median follow-up was 52 months (range 12-120 months). There were no differences between the groups in the 5-year recurrence-free survival (73.9 % vs. 79.7 %; p = 0.65), disease-specific survival (79.3 % vs. 83.6 %; p = 0.87), and overall survival (65.7 % vs. 80.3 %; p = 0.35). Hysteroscopic diagnosis in women with early-stage and high-grade endometrial cancer does not adversely affect the survival outcomes.

Identifiants

pubmed: 38118271
pii: S0301-2115(23)00871-0
doi: 10.1016/j.ejogrb.2023.12.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-71

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ahmet Namazov (A)

Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel. Electronic address: enamazov@gmail.com.

Limor Helpman (L)

Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel.

Ram Eitan (R)

Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel.

Zvi Vaknin (Z)

The Yitzhak Shamir Center (Formerly Assaf Harofeh Medical Center), Sackler School of Medicine, Tel Aviv University, Zerifin 70300, Israel.

Ofer Lavie (O)

Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Amnon Amit (A)

Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Tally Levy (T)

Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Holon, Israel.

Inbar Ben Shachar (IB)

Ziv Medical Center, Bar Ilan University, Zefat, Israel.

Ilan Atlas (I)

Poriya Medical Center, Bar Ilan University, Tiberia, Israel.

Ilan Bruchim (I)

Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Technion, Hedera, Israel.

Alon Ben Arie (AB)

Kaplan Medical Center, Hebrew University, Rehovot, Israel.

Ofer Gemer (O)

Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel.

Classifications MeSH